GSK acquires stake in Swiss BioVersys
Under the terms of the agreement, GSK will subscribe 12.3 million Swiss francs (around 12.6 million euros) to the company's latest Series C financing for a total amount of 44.9 million Swiss francs.
The Group also plans to deepen its collaboration with BioVersys, which specializes in the development of new antibiotic treatments to combat bacterial resistance.
In particular, it plans to support the development of BVL-GSK098, a small molecule currently in Phase 2a trials for the treatment of multi-drug-resistant pulmonary tuberculosis, one of the ten most deadly infections worldwide, causing 1.3 million deaths a year.
GSK and BioVersys say they want to make their new treatment available to patients 'as quickly as possible'.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction